ArticleEuropean journal of heart failure2022
Clinical effect of obesity on N-terminal pro-B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure.
Article in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Association between natriuretic peptides and C-reactive protein with frailty in heart failure: a systematic review and meta-analysis.Aging clinical and experimental research · 2024Pooled it
- Proteogenomic Profiling of Idiopathic Pulmonary Arterial Hypertension Identifies Sex-Differential Proteins and Candidate Therapeutic Targets.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Adipose Tissue, Natriuretic Peptides, and HFpEF: Clinical Implications of the Obesity Paradox.Biomedicines · 2026Review
- Tetranectin and Paraoxonase-1 as Markers of Heart Failure.Medicina (Kaunas, Lithuania) · 2026Review
- Gut Microbiota-Derived Trimethylamine N-Oxide and NT-proBNP in Heart Failure: A Critical Review of Diagnostic and Prognostic Value.Biomedicines · 2026Review
- Addressing Unmet Needs in Heart Failure with Preserved Ejection Fraction: Multi-Omics Approaches to Therapeutic Discovery.International journal of molecular sciences · 2026Review
- Efficacy and safety of levosimendan in acute heart failure patients with different body mass index: a multicenter, retrospective, observational real-world study.Frontiers in cardiovascular medicine · 2026Article
- Obesity in Heart Failure: Mechanistic, Diagnostic and Therapeutic Considerations.Cardiac failure review · 2026Review
- Acute dyspnoea in cancer patients: Prevalence of acute heart failure, resource use and diagnostic accuracy of natriuretic peptides.European journal of heart failure · 2025Article
- Article
- Adjusting natriuretic peptide decision limits for BMI for a more personalized diagnosis of heart failure.Advances in laboratory medicine · 2025Article
- Serum NT-ProBNP/Chloride Ratio Predicts Adverse Cardiovascular Outcomes in Patients with Acute Heart Failure.Biomedicines · 2025Article
- High-Complexity Questions and Their Answers for Everyday Heart Failure.Journal of clinical medicine · 2025Article
- Not All "Negatives" Are Created Equal - Understanding the Impact of Body Mass Index on B-Type Natriuretic Peptide Interpretation in Heart Failure.Journal of general internal medicine · 2025Article
- Body mass index modifies the major adverse cardiovascular and cerebral events risk of NT-proBNP in patients with acute coronary syndrome.Diabetology & metabolic syndrome · 2025Article
- Obesity-Related Phenotype of Heart Failure With Preserved Ejection Fraction: A Comprehensive Review.Cureus · 2025Review
- Observational
- Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity.Cardiovascular diabetology · 2025Review
- 2024 update in heart failure.ESC heart failure · 2025Review
- Cardiac Biomarkers in a Brazilian Indigenous Population Exposed to Arboviruses: A Cross-Sectional Study.Viruses · 2024Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsObese patients have lower natriuretic peptide concentrations. We hypothesized that adjusting the concentration of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for obesity could further increase its clinical utility in the early diagnosis of acute heart failure (AHF). METHODS AND
resultsThis hypothesis was tested in a prospective diagnostic study enrolling unselected patients presenting to the emergency department with acute dyspnoea. Two independent cardiologists/internists centrally adjudicated the final diagnosis using all individual patient information including cardiac imaging. NT-proBNP plasma concentrations were applied: first, using currently recommended cut-offs; second, using cut-offs lowered by 33% with body mass index (BMI) of 30-34.9 kg/m
conclusionsAdjusting NT-proBNP concentrations for obesity seems to further increase its clinical utility in the early diagnosis of AHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.